Long-term prognosis of adverse cardiovascular events in patients with chronic heart failure depending on the rs1143634 polymorphism of the interleukin-1β gene

The course and prognosis of chronic heart failure (CHF) are associated with the activation of inflammatory cascades, the severity of which is genetically determined.

Aim: To analyze adverse cardiovascular events in patients with chronic heart failure over 5 years depending on the rs1143634 polymorphism of the interleukin-1β gene.

Material and Methods. Clinical signs were studied, genotyping was carried out at the polymorphic locus rs1143634 of the IL-1β gene in patients with CHF of ischemic origin (n = 445, average age 66.4 ± 10.4 years). Information on patient outcomes over 5 years was obtained by telephone interview with endpoints: all-cause death, cardiovascular death, fatal and non-fatal cardiovascular events formed a composite endpoint. Time to event was analyzed using the Kaplan-Meier method; hazard ratio – Cox regression. Statistical processing was carried out in the Jamovi, R 4.3.1 programs.

Results and conclusions. The occurrence of genotypes of the rs1143634 polymorphism of the IL-1β gene in patients with CHF and the genetic control group did not differ and was commensurate with the theoretically expected Hardy–Weinberg equilibrium. Carriers of the TT genotype were characterized by a high level of inflammation and the development of myocardial infarction at a young age. In patients with CHF of the TT genotype, the risk of death from all causes is 2.85 times higher, achieving the combined endpoint is 3.3 times higher, fatal cerebral stroke is 17.1 times higher compared to CC, 14.9 times higher than compared to ST genotype. In patients with CHF and chronic kidney disease of the TT genotype, the risk of death from cerebral stroke is 29.33 times higher than the CC genotype, and 29.12 times higher for the CT genotype. In patients with CHF in combination with diabetes mellitus, the frequency of hospitalizations due to cardiac decompensation in the TT genotype is higher than in the CC and CT genotypes (χ₂ = 6.33, p = 0.042).

chronic heart failure; rs1143634 polymorphism of the IL-1β gene; prognosis; cardiovascular complications

1. Yndestad A., Damas J.K., Oie E., Ueland T., Gullestad L., Aukrust P. Role of inflammation in the progression of heart failure. Curr. Cardiol. Rep. 2007;9(3):236–241. DOI: 10.1007/bf02938356.

2. Teplyakov A.T., Shilov S.N., Popova A.A., Berezikova E.N., Grakova E.V., Neupokoeva M.N. et al. The role of proinflammatory cytokines in the development of anthracycline-induced heart failure. Siberian Journal of Clinical and Experimental Medicine. 2020;35(2):66–74. (In Russ.) DOI: 10.29001/2073-8552-2020-35-2-66-74.

3. Fang Y., Xie H., Lin Z. Association between IL-1β + 3954C/T polymorphism and myocardial infarction risk: A meta-analysis. Medicine (Baltimore). 2018;97(30):e11645. DOI: 10.1097/MD.0000000000011645.

4. Tabata N., Sueta D., Akasaka T., Arima Y., Sakamoto K., Yamamoto E. et al. Helicobacter pylori seropositivity in patients with interleukin-1 polymorphism is significantly associated with ST-segment elevation myocardial infarction. PLoS One. 2016;11(11):e0166240. DOI: 10.1371/journal.pone.0166240.

5. Chen Q., Wang W., Huang Zh., Huang D.L., Li T., Wang F. et al. Correlation of rs1122608 SNP with acute myocardial infarction susceptibility and clinical characteristics in a Chinese Han population: A case control study. The Anatolian Journal of Cardiology. 2018;19(4):249–258. DOI:10.14744/anatoljcardiol.2018.35002.

6. Serafin M., Kalinka J. The role of chosen polymorphism of gens coding cytokines IL-1ß, IL1ra, IL-6 and TNFalpha in the pathogenesis of the preterm delivery. Ginekol i Poloznictwo.2014;33(3):9–23.

7. Pociot F., Molvig J., Wogensen L., Worsaae H., Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur. J. Clin. Invest. 1992;22:396–402. DOI: 10.1111/j.1365-2362.

8. Latkovskis G., Licis N., Kalnins U. C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur. J. Immunogenet. 2004;31(5):207–213. DOI: 10.1111/j.1365-2370.2004.00476.x.

9. rs1143634. Ensembl is a genome browser. URL: http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=2:112832313-112833313;v=rs1143634;vdb=variation;vf=182624122 (08.10.2024).

10. Fadl M.A., Noor Аlgalil S.S. IL1 𝛽 exon 395 C/ Polymorphism potential genetic risk factor of heart diseases’ predisposition in Sudanese patients. Sudan Journal of Medical Sciences. 2020;15(4):399–407. DOI: 10.18502/sjms.v15i4.8162.

11. Pan Q., Hui D., Hu C. A variant of IL1B is associated with the risk and blood lipid levels of myocardial infarction in Eastern Chinese individuals. Immunol. Invest. 2022;51(5):1162–1169. DOI: 10.1080/08820139.2021.1914081.

12. Zakharyan E.A., Gritskevich O.Yu. The influence of single nucleotide polymorphisms of the IL1β, EDN1 and NOS3 genes on the individual genetic profile of patients with coronary heart disease in the Republic of Crimea. The Bulletin of Contemporary Clinical Medicine. 2023;16(6):31– 36. (In Russ.). DOI: 10.20969/VSKM.2023.16(6).31–36.

13. Topchieva L.V., Kurbatova I.V., Malysheva I.E., Korneva V.A., Topchieva A.V. Allelic polymorphism of genes involved in IL-1β production and predisposition of people to the development of arterial hypertension. Research Results in Biomedicine. 2023;9(1):53–70. (In Russ.). DOI: 10.18413/2658-6533-2023-9-1-0-4.

14. Mayanskaya S.D., Yakovleva N.F., Yakovlev A.V., Filipenko M.L., Voronina E.P., Berezikova E.N., et al. Polymorphism of interleukin-1β and interleukin-1 receptor antagonist genes in patients with chronic heart failure. Journal of heart failure. 2008;9(2):60–63. (In Russ.).

15. Teplyakov A.T., Shilov S.N., Berezikova E.N., Yakovleva N.F., Torim Yu.Yu., Kisteneva I.V. et al. Clinical and genetic determinants of the genes TNF-OS, IL-1/3 AND IL-1RA in the initiation and development of chronic heart failure in patients with coronary heart disease. Siberian Medical Journal (Tomsk). 2009;24(1):40–48. (In Russ.).

16. Kramer F., Voss S., Roessig L., Igl B.W., Butler J., Lam C.S.P. et al. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur. J. Heart Fail. 2020;22(9):1675–1683. DOI: 10.1002/ejhf.1787.

17. Zeybek U., Toptas B., Karaali Z.E., Kendir M., Cakmakoglu B. Effect of TNF-α and IL-1β genetic variants on the development of myocardial infarction in Turkish population. Mol. Biol. Rep. 2011;38(8):5453–5457. DOI: 10.1007/s11033-011-0701-x.

18. Coker A., Arman A., Soylu O., Tezel T., Yildirim A. Lack of association between IL-1 and IL-6 gene polymorphisms and myocardial infarction in Turkish population. Int. J. Immunogenet. 2011;38(3):2018. DOI: 10.1111/j.1744-313X.2010.00988.x.